公开(公告)号：US11932867B2

公开(公告)日：2024-03-19

申请号：US16609175

申请日：2018-04-25

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Brian Freed ,  Kirsten Anderson ,  Christina Roark ,  Jennifer Matsuda

IPC: C12N15/85 ,  A61K35/28 ,  A61K48/00 ,  C12N5/0789 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N15/85 ,  A01K67/0275 ,  A61K35/28 ,  C12N5/0647 ,  C12N9/22 ,  C12N15/11 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K48/00 ,  C12N2310/20 ,  C12N2740/15042 ,  C12N2750/14142 ,  C12N2800/80

Abstract: Methods of preventing or treating rheumatoid arthritis (RA) in a subject by introducing the DRB1*04:01K71E mutation that is resistant to RA. The resistant allele is introduced into the subject having or at risk of developing RA, using a HLA CRISPR/Cas9 vector that targets codon 71 in the HLA allele DRB1*04:01, introducing a single A to G point mutation in codon 71 by homology directed repair to alter the lysine at position 71 of the expressed protein to glutamic acid. This modified allele is affected in the subject's hematopoietic stem cells, which are then expanded and transplanted back into the patient. This microgene therapy confers RA-resistance via an autologous transplant. The invention includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to modify the HLA DRB1*04:01 allele.

公开(公告)号：US20240327862A1

公开(公告)日：2024-10-03

申请号：US18605149

申请日：2024-03-14

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE ,  NATIONAL JEWISH HEALTH

Inventor： Brian Freed ,  Kirsten Anderson ,  Christina Roark ,  Jennifer Matsuda

IPC: C12N15/85 ,  A01K67/0275 ,  A61K35/28 ,  A61K48/00 ,  C12N5/0789 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N15/85 ,  A01K67/0275 ,  A61K35/28 ,  C12N5/0647 ,  C12N9/22 ,  C12N15/11 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K48/00 ,  C12N2310/20 ,  C12N2740/15042 ,  C12N2750/14142 ,  C12N2800/80

Abstract: Methods of preventing or treating rheumatoid arthritis (RA) in a subject by introducing the DRB1*04:01K71E mutation that is resistant to RA. The resistant allele is introduced into the subject having or at risk of developing RA, using a HLA CRISPR/Cas9 vector that targets codon 71 in the HLA allele DRB1*04:01, introducing a single A to G point mutation in codon 71 by homology directed repair to alter the lysine at position 71 of the expressed protein to glutamic acid. This modified allele is affected in the subject's hematopoietic stem cells, which are then expanded and transplanted back into the patient. This microgene therapy confers RA-resistance via an autologous transplant. The invention includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to modify the HLA DRB1*04:01 allele.